HRP20010194B1 - Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments - Google Patents

Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments

Info

Publication number
HRP20010194B1
HRP20010194B1 HR20010194A HRP20010194A HRP20010194B1 HR P20010194 B1 HRP20010194 B1 HR P20010194B1 HR 20010194 A HR20010194 A HR 20010194A HR P20010194 A HRP20010194 A HR P20010194A HR P20010194 B1 HRP20010194 B1 HR P20010194B1
Authority
HR
Croatia
Prior art keywords
group
unbranched
branched
alkyl
polysubstituted
Prior art date
Application number
HR20010194A
Other languages
Croatian (hr)
Inventor
Eickmeier Christian
Buerger Erich
Matthias Blech Stefan
Roos Otto
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg. filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg.
Publication of HRP20010194A2 publication Critical patent/HRP20010194A2/en
Publication of HRP20010194B1 publication Critical patent/HRP20010194B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Derivati benzoilgvanidina opće formule I, naznačeni time, daR1 predstavlja C1-C8-alkil, heteroaril, nesupstituiran ili jednostruko ili višestruko supstituiran s razgranatom ili nerazgranatom C1-C4-alkilnom skupinom, cikloalkilnom skupinom, razgranatom ili nerazgranatom C1-C4-alkoksi skupinom, NH2-skupinom ili s primarnom ili sekundarnom amino skupinom, trifluormetilnom skupinom, cijano ili nitro skupinom ili halogenom, aril nesupstituiran ili jednostruko ili višestruko supstituiran s razgranatom ili nerazgranatom C1-C4-alkilnom skupinom, razgranatom ili nerazgranatom C1-C4-alkoksi skupinom, NH2-skupinom ili s primarnom ili sekundarnom amino skupinom, trifluormetilnom skupinom, cijano ili nitro skupinom ili halogenom, ili s 5- ili 6-članim heteroarilnim ostatkom, koji može sadržavati jedan, dva, tri, četilri ili pet, međusobno jednakih ili različitih heteroatoma iz skupine koju čine dušik, kisik ili sumpor, alkilaril nesupstituiran ili jednostruko ili višestruko supstituiran u arilnom i/ili alkilnom dijelu strukture s razgranatom ili nerazgranatom C1-C4-alkilnom skupinom, razgranatom ili nerazgranatom C1-C4-alkoksi skupinom, NH2-skupinom ili s primarnom ili sekundarnom amino skupinom, trifluormetilnom skupinom, cijano ili nitro skupinom ili halogenom, prema potrebi u obliku pojedinačnih tautomera ili prema potrebi enantiomera i njihovih smjesa, kao i u obliku slobodnih baza ili odgovarajućih kiselinskih adicijskih soli s farmakološki prihvatljivim kiselinama. Patent sadrži još 8 patentnih zahtjeva.Benzoylguanidine derivatives of general formula I, characterized in that R 1 represents C 1 -C 8 -alkyl, heteroaryl, unsubstituted or mono- or polysubstituted by a branched or unbranched C 1 -C 4 -alkyl group, a cycloalkyl group, a branched or unbranched NH 2 alkoxy -group or with a primary or secondary amino group, trifluoromethyl group, cyano or nitro group or halogen, aryl unsubstituted or mono- or polysubstituted by a branched or unbranched C1-C4-alkyl group, branched or unbranched C1-C4-alkoxy a group or with a primary or secondary amino group, a trifluoromethyl group, a cyano or nitro group or a halogen, or with a 5- or 6-membered heteroaryl residue, which may contain one, two, three, four or five, identical or different heteroatoms from the group consisting of nitrogen, oxygen or sulfur, alkylaryl unsubstituted or mono- or polysubstituted in aryl and / or an alkyl portion of the structure with a branched or unbranched C1-C4-alkyl group, a branched or unbranched C1-C4-alkoxy group, an NH2 group or with a primary or secondary amino group, a trifluoromethyl group, a cyano or nitro group or a halogen, as appropriate. in the form of individual tautomers or optionally enantiomers and mixtures thereof, as well as in the form of free bases or corresponding acid addition salts with pharmacologically acceptable acids. The patent contains 8 more patent claims.

HR20010194A 1998-09-22 2001-03-15 Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments HRP20010194B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19843489A DE19843489B4 (en) 1998-09-22 1998-09-22 Benzoylguanidine derivatives having advantageous properties, processes for their preparation and their use in the preparation of medicaments, and pharmaceutical compositions containing them
PCT/EP1999/006857 WO2000017176A2 (en) 1998-09-22 1999-09-16 Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments

Publications (2)

Publication Number Publication Date
HRP20010194A2 HRP20010194A2 (en) 2002-04-30
HRP20010194B1 true HRP20010194B1 (en) 2009-05-31

Family

ID=7881872

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010194A HRP20010194B1 (en) 1998-09-22 2001-03-15 Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments

Country Status (35)

Country Link
EP (1) EP1165534B1 (en)
JP (1) JP3817425B2 (en)
KR (1) KR100621821B1 (en)
CN (1) CN1166654C (en)
AR (1) AR023668A1 (en)
AT (1) ATE288425T1 (en)
AU (1) AU764819C (en)
BG (1) BG64985B1 (en)
BR (1) BR9913107A (en)
CA (1) CA2345006C (en)
CO (1) CO5150207A1 (en)
CZ (1) CZ300158B6 (en)
DE (2) DE19843489B4 (en)
EA (1) EA004687B1 (en)
EE (1) EE04749B1 (en)
EG (1) EG23757A (en)
ES (1) ES2237951T3 (en)
HK (1) HK1043367B (en)
HR (1) HRP20010194B1 (en)
HU (1) HU228955B1 (en)
ID (1) ID27759A (en)
IL (1) IL141805A (en)
MY (1) MY121362A (en)
NO (1) NO317993B1 (en)
NZ (1) NZ511167A (en)
PE (1) PE20001085A1 (en)
PL (1) PL195291B1 (en)
PT (1) PT1165534E (en)
RS (1) RS49971B (en)
SA (1) SA99200474B1 (en)
SK (1) SK285578B6 (en)
TR (1) TR200100801T2 (en)
TW (1) TWI221841B (en)
WO (1) WO2000017176A2 (en)
ZA (1) ZA200101212B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10106970A1 (en) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma New benzoylguanidine salt
US6730678B2 (en) * 2001-02-15 2004-05-04 Boehringer Ingelheim Pharma Kg Benzoylguanidine salt and hydrates thereof
US6982256B2 (en) 2001-09-07 2006-01-03 Boehringer Ingelheim Pharma Kg Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration
DE10144030A1 (en) * 2001-09-07 2003-03-27 Boehringer Ingelheim Pharma Composition containing 4-piperazino-benzoylguanidine derivative, useful e.g. for treating cardiac infarction, containing component to improve local tolerance, e.g. beta-cyclodextrin derivative or polymer
FR2871157A1 (en) * 2004-06-04 2005-12-09 Aventis Pharma Sa BIARYL AROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF
JP2011527677A (en) * 2008-07-08 2011-11-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyrrolidinyl and piperidinyl compounds useful as NHE-1 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19601303A1 (en) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Novel benzoylguanidine derivatives, process for their preparation and their use in the manufacture of medicaments

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19601303A1 (en) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Novel benzoylguanidine derivatives, process for their preparation and their use in the manufacture of medicaments

Also Published As

Publication number Publication date
EG23757A (en) 2007-08-08
CA2345006A1 (en) 2000-03-30
EA004687B1 (en) 2004-06-24
SK3962001A3 (en) 2001-10-08
BG105326A (en) 2001-11-30
PL347234A1 (en) 2002-03-25
ID27759A (en) 2001-04-26
SK285578B6 (en) 2007-04-05
IL141805A (en) 2005-12-18
IL141805A0 (en) 2002-03-10
EE04749B1 (en) 2006-12-15
CZ300158B6 (en) 2009-02-25
AU764819C (en) 2004-12-16
EA200100317A1 (en) 2001-10-22
HK1043367B (en) 2005-02-25
BG64985B1 (en) 2006-11-30
AR023668A1 (en) 2002-09-04
PT1165534E (en) 2005-04-29
PE20001085A1 (en) 2000-10-25
EE200100178A (en) 2002-10-15
YU21501A (en) 2004-03-12
NZ511167A (en) 2003-12-19
NO20011428D0 (en) 2001-03-21
EP1165534A2 (en) 2002-01-02
HUP0200225A2 (en) 2002-06-29
ATE288425T1 (en) 2005-02-15
HU228955B1 (en) 2013-07-29
CO5150207A1 (en) 2002-04-29
BR9913107A (en) 2002-06-11
CN1342153A (en) 2002-03-27
PL195291B1 (en) 2007-08-31
DE19843489B4 (en) 2006-12-21
CN1166654C (en) 2004-09-15
JP2002538077A (en) 2002-11-12
EP1165534B1 (en) 2005-02-02
WO2000017176A2 (en) 2000-03-30
HRP20010194A2 (en) 2002-04-30
RS49971B (en) 2008-09-29
TWI221841B (en) 2004-10-11
SA99200474B1 (en) 2006-06-10
AU764819B2 (en) 2003-08-28
ES2237951T3 (en) 2005-08-01
DE19843489A1 (en) 2000-03-23
JP3817425B2 (en) 2006-09-06
DE59911568D1 (en) 2005-03-10
HUP0200225A3 (en) 2002-12-28
NO20011428L (en) 2001-03-21
HK1043367A1 (en) 2002-09-13
CA2345006C (en) 2007-11-13
MY121362A (en) 2006-01-28
CZ20011047A3 (en) 2001-08-15
NO317993B1 (en) 2005-01-17
KR100621821B1 (en) 2006-09-13
WO2000017176A3 (en) 2001-10-11
ZA200101212B (en) 2002-10-04
AU6465999A (en) 2000-04-10
TR200100801T2 (en) 2002-04-22
KR20010079884A (en) 2001-08-22

Similar Documents

Publication Publication Date Title
HUP0100779A2 (en) Novel derivatives of 3,3-diphenylpropylamines
EA200300211A1 (en) AZABICCAL COMPOUNDS, METHOD OF THEIR PRODUCTION AND THEIR APPLICATION AS A MEDICINE, IN PARTICULAR AS ANTIBACTERIAL MEANS
HRP20090151T3 (en) Indozolone derivatives as 11b-hsd1 inhibitors
IS4588A (en) Benzimidazole compounds, pharmaceutical compositions containing the compounds and their use
PL338129A1 (en) Crystalline form of a derivative of n-phenyl-2-dipyrimidin amine, methods of obtaining same and apllication thereof
HUP0402026A2 (en) 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists, process for their preparation and pharmaceutical compositions containing them
BRPI0312811A8 (en) 3-z- [1- (4- (n - ((4-methyl-piperazin-1-yl) methylcarbonyl) -n-methyl-amino) anilino) -1-phenylmethylene] -6-methoxycarbonyl-2 monoethane sulfonate -indolinone, its use, and pharmaceutical composition
RS52326B (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors
EP1344525A4 (en) Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
MEP52408A (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
RS51226B (en) Azapeptide derivatives as hiv protease inhibitors
BR0009411A (en) Substituted aniline compound, and, process for the preparation and use of compounds
NO974843D0 (en) Benzimidazole compounds, pharmaceutical compositions containing the compounds and their applications
RS51681B (en) Piperazinyl and diazapanyl benzamides and benzthioamides
UY27618A1 (en) ESTERS HYDROXAMATE ACID N- (4-PHENYL-SUBSTITUTED) -ANTRANILIC
EA200500690A1 (en) NEW PYRIDOPYRIMIDINON COMPOUNDS, METHOD OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
HRP20010194B1 (en) Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments
PE20050329A1 (en) NICOTINAMIDE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE PDE4
BR0312593A (en) Urea and urethane substituted acylureas, process for their production and application
DE3851388D1 (en) Substituted N- (3-hydroxy-4-piperidinyl) benzamides.
NO20023001L (en) Substituted piperazine derivatives as MTP inhibitors
NO20002124L (en) Novel Carboxylic Acid Derivatives with Amide Side Chains, Their Preparation and Use as Endothelin Receptor Antagonists
DE69910083D1 (en) CATECHOLHYDRAZONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ES2077878T3 (en) SUBSTITUTED DERIVATIVES OF AMINO ACID AMIDES, THEIR OBTAINING AND THEIR USE AS FUNGICIDES.
ATE348800T1 (en) 4'-METHANSULFONYLBIPHENYL DERIVATIVES AS HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITORS

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG., DE

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20150824

Year of fee payment: 17

PBON Lapse due to non-payment of renewal fee

Effective date: 20160916